Skip to main content
SpringerLink
Log in

Economic Impact of Infections and Antibiotics

  • Chapter
  • First Online:
Sepsis

Abstract

In this chapter, we review several aspects with respect to the burden of infectious diseases, its impact in morbidity and mortality, and its economic burden. Furthermore, we referenced the actual situation with relation to the use of antimicrobial, the resistance problem and misuse of antibiotic, and the economic impact in the health systems.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. IHME. GBD history. Seattle, WA: Institute for Health Metrics and Evaluation; 2017. Accessed 9 Mar 2017. http://www.healthdata.org/gbd/about/history

    Google Scholar 

  2. WHO (2014) Metrics: disability-adjusted life year (DALY). WHO, Geneva. http://www.who.int/healthinfo/global_burden_disease/metrics_daly/en/. Accessed 5 Mar 2017.

  3. Alvis-Guzmán N, Valenzuela MT. Los QALYs y DALYs como indicadores sintéticos de salud. Rev Med Chil. 2010;138:83–7. http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872010001000005&lng=en&nrm=iso&tlng=en. Accessed 5 Mar 2017

    Google Scholar 

  4. Murray CJ, Lopez AD. Burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. http://apps.who.int/iris/bitstream/10665/41864/1/0965546608_eng.pdf. Accessed 3 Mar 2017.

  5. Omran AR. The epidemiologic transition: a theory of the epidemiology of population change. Milbank Mem Fund Q. 1971;49(4):509–38. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2690264/pdf/milq0083-0398.pdf. Accessed 6 Mar 2017

    Article  CAS  PubMed  Google Scholar 

  6. World Health Organization. The top 10 causes of death. Geneva: WHO; 2017. http://www.who.int/mediacentre/factsheets/fs310/en/. Accessed 16 Mar 2017

    Google Scholar 

  7. Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459–544. http://linkinghub.elsevier.com/retrieve/pii/S0140673616310121. Accessed 4 Feb 2017

    Article  Google Scholar 

  8. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Hay SI, Okiro EA, Gething PW, Patil AP, Tatem AJ, Guerra CA, et al. Estimating the global clinical burden of Plasmodium falciparum malaria in 2007. PLoS Med. 2010;7(6):e1000290.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Rogers WO, Sem R, Tero T, Chim P, Lim P, Muth S, et al. Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malar J. 2009;8:10.

    Article  PubMed  PubMed Central  Google Scholar 

  11. GBD results tool. GHDx. http://ghdx.healthdata.org/gbd-results-tool. Accessed 5 Mar 2017.

  12. Neill JO’. Antimicrobial resistance: tackling a crisis for the health and wealth of nations the review on antimicrobial resistance chaired. Review paper – tackling a crisis for the health and wealth of nations_1.pdf. 2014. https://amr-review.org/sites/default/files/AMR. Accessed 14 Apr 2017.

  13. Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014;14(8):742–50. http://linkinghub.elsevier.com/retrieve/pii/S1473309914707807. Accessed 13 Apr 2017

    Article  PubMed  Google Scholar 

  14. The Lancet Infectious Diseases. Antibiotic research priorities: ready, set, now go. Lancet Infect Dis. 2017;17(4):349. http://linkinghub.elsevier.com/retrieve/pii/S1473309917301408. Accessed 13 Apr 2017

    Article  CAS  PubMed  Google Scholar 

  15. Villegas MFKE-VSRCH-GCJPM V. Improved outcomes when antibiotic prescribing guidelines are followed by healthcare providers: a Colombian Example to encourage adherence in hospital settings. .2017; https://www.cambridge.org/core/services/aop-cambridge-core/content/view/0DEFEB6CEF70B9888A6AAA200B65247F/S0899823X17000459a.pdf/improved_outcomes_when_antibiotic_prescribing_guidelines_are_followed_by_healthcare_providers_a_colombian_example_to_encourage_. Accessed 13 Apr 2017.

  16. Kariv G, Paul M, Shani V, Muchtar E, Leibovici L. Benchmarking inappropriate empirical antibiotic treatment. Clin Microbiol Infect. 2013;19(7):629–33.

    Article  CAS  PubMed  Google Scholar 

  17. Dreser A, Wirtz VJ, Corbett KK, Echániz G. .Uso de antibióticos en México: revisión de problemas y políticas http://www.scielo.org.mx/pdf/spm/v50s4/09.pdf. Accessed 15 Apr 2017.

  18. Goff DA, Kullar R, Goldstein EJC, Gilchrist M, Nathwani D, Cheng AC, et al. A global call from five countries to collaborate in antibiotic stewardship: united we succeed, divided we might fail. 2017. http://basesdedatos.unicartagena.edu.co:2071/S1473309916303863/1-s2.0-S1473309916303863-main.pdf?_tid=34b035a2-2233-11e7-95b0-00000aacb362&acdnat=1492299078_d4dbbcf5e1edc65767444e1b95c2637b. Accessed 15 Apr 2017.

  19. Centers for Diseases Control and Prevention. Antibiotic resistance threats in the United States, 2013. .2013. https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. Accessed 13 Apr 2017.

  20. Alsan M, Schoemaker L, Eggleston K, Kammili N, Kolli P, Bhattacharya J. Out-of-pocket health expenditures and antimicrobial resistance in low- and middle-income countries. Lancet Infect Dis. 2015;15(10):1203–10.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Bhutta Z. Drug resistant infections in poor countries: a major burden on children. BMJ. 2008;336:948.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Lemos EV, De La Hoz FP, Alvis N, Einarson TR, Quevedo E, Casta-Neda C, et al. Impact of carbapenem resistance on clinical and economic outcomes among patients with Acinetobacter baumannii infection in Colombia. Clin Microbiol Infect. 2014;20:174–80.

    Article  CAS  PubMed  Google Scholar 

  23. Rodríguez-Burbano L, De FP, Hoz L, Leal-Castro AL. Costo de neumonía nosocomial no asociada a ventilación en el Hospital Universitario de Santander. Rev Salud Publica. 2013;15(2):196.

    PubMed  Google Scholar 

  24. Rodríguez-Burbano L, De FP, Hoz L, Leal-Castro AL. Costo de infección de vías urinarias asociada a sonda vesical en un hospital universitario de Santander, Colombia Costs of infection associated with urinary bladder probes in a teaching hospital in Santander, Colombia. Rev Salud Publica. 2016;18(1):104.

    Article  PubMed  Google Scholar 

  25. Navarrete-Navarro S, Armengol-Sánchez G. Costos secundarios por infecciones nosocomiales en dos unidades pediátricas de cuidados intensivos. Salud Publica Mex. 1999;41(Suppl 1):S51–8.

    Article  PubMed  Google Scholar 

  26. Brenner P, Nercelles P, Pohlenz M, Otaíza F, Alumnos Y, Magister En D, et al. Costo de las infecciones intrahospitalarias en hospitales chilenos de alta y mediana complejidad Cost of nosocomial infections in Chilean hospitals. Rev Chil Infect. 2003;20(4):285–90.

    Article  Google Scholar 

  27. Center for Disease Dynamics E&P. 2015 state of the world’s antibiotics. Washington, DC: CDDEP; 2015. https://cddep.org/sites/default/files/swa_2015_final.pdf. Accessed 13 Apr 2017

    Google Scholar 

  28. Wellbery C. Curbing inappropriate antibiotic prescribing: what works? Am Fam Physician. 2016;94(3):203–4. http://www.aafp.org/afp/2016/0801/p203.pdf. Accessed 14 Apr 2017

    PubMed  Google Scholar 

  29. GDP growth (annual %). Data. http://data.worldbank.org/indicator/NY.GDP.MKTP.KD.ZG?view=chart. Accessed 16 Apr 2017.

  30. Health expenditure, total (% of GDP). Data. http://data.worldbank.org/indicator/SH.XPD.TOTL.ZS. Accessed 16 Apr 2017.

  31. Kassebaum NJ, Arora M, Barber RM, Bhutta ZA, Brown J, Carter A, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1603–58. http://linkinghub.elsevier.com/retrieve/pii/S014067361631460X. Accessed 3 Mar 2017

    Article  Google Scholar 

  32. Aitken M. .Outlook for global medicines through 2021. 2016. www.quintilesimsinstitute.org. Accessed 5 Mar 2017.

    Google Scholar 

  33. Centers for Medicare & Medicaid Services. NHE-fact-sheet. 2017. https://www.cms.gov/research-statistics-data-and-systems/statistics-trends-and-reports/nationalhealthexpenddata/nhe-fact-sheet.html. Accessed 13 Apr 2017.

  34. IMS I for HI. Avoidable costs in U.S. Healthcare. NJ 07054 USA. 2013. http://www.imshealth.com/en/thought-leadership/quintilesims-institute/reports/avoidable-costs. Accessed 27 Apr 2017.

  35. Arizpe A, Reveles KR, Aitken SL. Regional variation in antibiotic prescribing among medicare part D enrollees. .2013. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5148872/pdf/12879_2016_Article_2091.pdf. Accessed 15 May 2017.

Download references

Author information

Authors and Affiliations

  1. Health Economics Research Group, Universidad de Cartagena, Avenida del consulado Campus Piedra de Bolivar, Cartagena, Bolivar, 130001, Colombia

    Nelson Alvis-Guzman MD, MPH, PhD & Hernando Pinzon-Redondo MD

  2. Universidad de la Costa, Barranquilla, Colombia

    Nelson Alvis-Guzman MD, MPH, PhD

  3. Universidad Nacional de Colombia, Bogotá, Colombia

    Fernando De la Hoz-Restrepo MD, MPH, PhD

Authors
  1. Nelson Alvis-Guzman MD, MPH, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fernando De la Hoz-Restrepo MD, MPH, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hernando Pinzon-Redondo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nelson Alvis-Guzman MD, MPH, PhD .

Editor information

Editors and Affiliations

  1. Department of Internal Medicine Pulmonary Medicine and Critical Care Hospital Santa Clara, Universidad del Bosque, Bogotá, Colombia

    Guillermo Ortiz-Ruiz

  2. Department of Critical Care Clínica Gestión Salud, Universidad de Cartagena, Cartagena, Colombia

    Carmelo Dueñas-Castell

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Science+Business Media LLC

About this chapter

Cite this chapter

Alvis-Guzman, N., De la Hoz-Restrepo, F., Pinzon-Redondo, H. (2018). Economic Impact of Infections and Antibiotics. In: Ortiz-Ruiz, G., Dueñas-Castell, C. (eds) Sepsis. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-7334-7_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-7334-7_2

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-7332-3

  • Online ISBN: 978-1-4939-7334-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation